BIOMAT Database Logo BIOMAT Database Logo

Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. 2021

Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
Pharmacology and Toxicology Section, CDB, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, c/Villarroel, 170, 08036 Barcelona, Spain; Biomedical Research Center in Hepatic and Digestive Diseases (CIBERehd), Instituto de Salud Carlos III, c/Sinesio Delgado 4, 28029 Madrid, Spain. Electronic address: omillan@clinic.cat.

This study evaluate the potential of plasmatic CXCL-10 (pCXCL-10) as a pre&post transplantation prognostic and diagnostic biomarker of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and subclinical rejection (SCR) risk in adult kidney recipients considering BKV and CMV infections as possible clinical confounder factors. Twenty-eight of 100 patients included experienced rejection (TCMR:14; ABMR:14); 8 SCR; 13 and 16 were diagnosed with BKV and CMV infection, respectively. Pre-transplantation pCXCL-10 was significantly increased in TCMR and ABMR and post-transplantation in TCMR, ABMR and SCR compared with nonrejectors. All CMV+ patients showed pCXCL-10 levels above the cutoff values established for rejection whereas the 80% of BKV+ patients showed pCXCL-10 concentration < 100 pg/mL. pCXCL-10 could improve pre-transplantation patient stratification and immunosuppressive treatment selection according to rejection risk; and after kidney transplantation could be a potential early prognostic biomarker for rejection. Clinical confounding factor in BKV+ and particularly in CMV+ patients must be discarded.

UI MeSH Term Description Entries
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001739 BK Virus A species of POLYOMAVIRUS apparently infecting over 90% of children but not clearly associated with any clinical illness in childhood. The virus remains latent in the body throughout life and can be reactivated under certain circumstances. BK polyomavirus,Human Polyomavirus BK,Polyomavirus, BK,Polyomavirus hominis 1,Polyomavirus BK, Human
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
A plasmatic score using a miRNA signature and CXCL-10 for accurate prediction and diagnosis of liver allograft rejection.
January 2023, Frontiers in immunology,
Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
Reduced PARP1 as a Serum Biomarker for Graft Rejection in Kidney Transplantation.
January 2015, Journal of proteomics & bioinformatics,
Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
Subclinical rejection-free diagnostic after kidney transplantation using blood gene expression.
June 2023, Kidney international,
Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
Urinary Human Epididymis Secretory Protein 4 as a Useful Biomarker for Subclinical Acute Rejection Three Months after Kidney Transplantation.
September 2019, International journal of molecular sciences,
Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
Natural history, risk factors, and impact of subclinical rejection in kidney transplantation.
July 2004, Transplantation,
Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
The Problem of Subclinical Antibody-mediated Rejection in Kidney Transplantation.
June 2021, Transplantation,
Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease.
December 2014, Kidney international,
Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
The exosome as a novel predictive/diagnostic biomarker of rejection in the field of transplantation.
June 2019, Clinical immunology (Orlando, Fla.),
Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
Pre-transplant serum level of CXCL9 as a biomarker of acute rejection and graft failure risk in kidney transplantation.
May 2010, Transplant international : official journal of the European Society for Organ Transplantation,
Olga Millán, and Jordi Rovira, and Lluis Guirado, and Cristina Espinosa, and Klemens Budde, and Claudia Sommerer, and Gaston J Piñeiro, and Fritz Diekmann, and Mercè Brunet
Early subclinical rejection as a risk factor for late chronic humoral rejection.
January 2012, Transplantation,
Copied contents to your clipboard!